{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:05:19Z","timestamp":1784239519865,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dose-escalation to above 80\u00a0Gy during external beam radiotherapy for localised prostate cancer leads to improved oncological outcomes but also substantially increased rectal toxicity. The aim of this study was to demonstrate the safety and efficacy of escalating the dose to 82\u00a0Gy following insertion of a peri-rectal hydrogel spacer (HS) prior to radiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a single arm, open-label, prospective study of men with localised prostate cancer who were prescribed a course of intensity modulated radiotherapy escalated to 82\u00a0Gy in 2\u00a0Gy fractions following insertion of the SpaceOAR\u2122 HS (Boston Scientific, Marlborough, MA). Patients were prescribed a standard course of 78\u00a0Gy in 2\u00a0Gy fractions where rectal dose constraints could not be met for the 82\u00a0Gy plan. The co-primary endpoints were the rate of grade 3 gastrointestinal (GI) and genitourinary (GU) adverse events (CTCAE, v4), and patient-reported quality of life (QoL) (EORTC QLQ-C30 and PR25 modules), up to 37.5\u00a0months post-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy patients received treatment on the study, with 64 (91.4%) receiving an 82\u00a0Gy treatment course. The median follow-up time post-treatment was 37.4\u00a0months. The rate of radiotherapy-related grade 3 GI and GU adverse events was 0% and 2.9%, respectively. There were 2 (2.9%) grade 3 adverse events related to insertion of the HS. Only small and transient declines in QoL were observed; there was no clinically or statistically significant decline in QoL beyond 13.5\u00a0months and up to 37.5\u00a0months post-treatment, compared to baseline. No late RTOG-defined grade\u2009\u2265\u20092 GI toxicity was observed, with no GI toxicity observed in any patient at 37.5\u00a0months post-treatment. Nine (12.9%) patients met criteria for biochemical failure within the follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dose-escalation to 82\u00a0Gy, facilitated by use of a hydrogel spacer, is safe and feasible, with minimal toxicity up to 37.5\u00a0months post-treatment when compared to rates of rectal toxicity in previous dose-escalation trials up to 80\u00a0Gy. Trials with longer follow-up of oncological and functional outcomes are required to robustly demonstrate a sustained widening of the therapeutic window.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Australian New Zealand Clinical Trials Registry, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/anzctr.org.au\/ACTRN12621000056897\">ACTRN12621000056897<\/jats:ext-link>, 22\/01\/2021. Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02103-5","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T17:03:32Z","timestamp":1658768612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dose-escalated radiotherapy to 82\u00a0Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Andrew W.","family":"See","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree","family":"Appu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Liodakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Pandeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd M. L.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean P.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, den Broeck TV, Cumberbatch MG, Santis MD, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362.","journal-title":"Eur Urol"},{"key":"2103_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","volume":"80","author":"V Beckendorf","year":"2011","unstructured":"Beckendorf V, Guerif S, Le Pris\u00e9 E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol. 2011;80:1056\u201363.","journal-title":"Int J Radiat Oncol"},{"key":"2103_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","volume":"70","author":"DA Kuban","year":"2008","unstructured":"Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;4: e180039.","journal-title":"JAMA Oncol"},{"key":"2103_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ijrobp.2007.01.008","volume":"68","author":"TN Eade","year":"2007","unstructured":"Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68:682\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","volume":"60","author":"MJ Zelefsky","year":"2011","unstructured":"Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol. 2011;60:1133\u20139.","journal-title":"Eur Urol"},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.ijrobp.2011.04.005","volume":"82","author":"N Pahlajani","year":"2012","unstructured":"Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DYT, Horwitz EM, Hanks GE, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:1949\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2217\/fon.13.223","volume":"10","author":"M Pinkawa","year":"2014","unstructured":"Pinkawa M. Spacer application for prostate cancer radiation therapy. Future Oncol. 2014;10:851\u201364.","journal-title":"Future Oncol"},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1748-717X-8-96","volume":"8","author":"E Gez","year":"2013","unstructured":"Gez E, Cytron S, Ben Yosef R, London D, Corn BW, Alani S, et al. Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol. 2013;8:96.","journal-title":"Radiat Oncol"},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijrobp.2007.02.034","volume":"69","author":"PJ Prada","year":"2007","unstructured":"Prada PJ, Fern\u00e1ndez J, Martinez AA, de la R\u00faa A, Gonzalez JM, Fernandez JM, et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys. 2007;69:95\u2013102.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"2103_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2407-13-27","volume":"22","author":"F Eckert","year":"2013","unstructured":"Eckert F, Alloussi S, Paulsen F, Bamberg M, Zips D, Spillner P, et al. Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer. 2013;22(13):27.","journal-title":"BMC Cancer"},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1748-717X-9-96","volume":"9","author":"M Uhl","year":"2014","unstructured":"Uhl M, Herfarth K, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, et al. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. Radiat Oncol. 2014;9:96.","journal-title":"Radiat Oncol"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","volume":"92","author":"N Mariados","year":"2015","unstructured":"Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:971\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.radonc.2013.01.007","volume":"106","author":"C Melchert","year":"2013","unstructured":"Melchert C, Gez E, Bohlen G, Scarzello G, Koziol I, Anscher M, et al. Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol. 2013;106:210\u20134.","journal-title":"Radiother Oncol"},{"key":"2103_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8221","volume":"3","author":"LE Miller","year":"2020","unstructured":"Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3: e208221.","journal-title":"JAMA Netw Open"},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/1754-9485.12945","volume":"63","author":"BL Te Velde","year":"2019","unstructured":"Te Velde BL, Westhuyzen J, Awad N, Wood M, Shakespeare TP. Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion. J Med Imaging Radiat Oncol. 2019;63:836\u201341.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"E647","DOI":"10.1111\/j.1464-410X.2012.11373.x","volume":"110","author":"G Hatiboglu","year":"2012","unstructured":"Hatiboglu G, Pinkawa M, Vall\u00e9e JP, Hadaschik B, Hohenfellner M. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int. 2012;110:E647-652.","journal-title":"BJU Int"},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","volume":"44","author":"G van Andel","year":"2008","unstructured":"van Andel G, Bottomley A, Foss\u00e5 SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418\u201324.","journal-title":"Eur J Cancer"},{"key":"2103_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejmp.2015.10.091","volume":"32","author":"JH Chang","year":"2016","unstructured":"Chang JH, Gehrke C, Prabhakar R, Gill S, Wada M, Joon DL, et al. RADBIOMOD: a simple program for utilising biological modelling in radiotherapy plan evaluation. Phys Med. 2016;32:248\u201354.","journal-title":"Phys Med"},{"issue":"Suppl","key":"2103_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijrobp.2009.03.078","volume":"76","author":"JM Michalski","year":"2010","unstructured":"Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose\u2013volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76(Suppl):123\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/9780470773666","volume-title":"Statistical methods in medical research","author":"P Armitage","year":"2002","unstructured":"Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Wiley-Blackwell; 2002.","edition":"4"},{"issue":"1","key":"2103_CR24","first-page":"221","volume":"5","author":"PJ Huber","year":"1967","unstructured":"Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proc Fifth Berkeley Symp Math Stat Probab. 1967;5(1):221\u201334.","journal-title":"Proc Fifth Berkeley Symp Math Stat Probab"},{"key":"2103_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/1912526","volume":"50","author":"H White","year":"1982","unstructured":"White H. Maximum likelihood estimation of misspecified models. Econometrica. 1982;50:1\u201325.","journal-title":"Econometrica"},{"key":"2103_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29:89\u201396.","journal-title":"J Clin Oncol"},{"key":"2103_CR27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","volume":"18","author":"GM Duchesne","year":"2017","unstructured":"Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01\u201303 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017;18:1192\u2013201.","journal-title":"Lancet Oncol"},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1177\/1536867X1501500407","volume":"15","author":"C Bascoul-Mollevi","year":"2015","unstructured":"Bascoul-Mollevi C, Castan F, Azria D, Gourgou-Bourgade S. EORTC QLQ-C30 descriptive analysis with the qlqc30 command. Stata J. 2015;15:1060\u201374.","journal-title":"Stata J"},{"key":"2103_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","volume":"24","author":"A Anota","year":"2015","unstructured":"Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res. 2015;24:5\u201318.","journal-title":"Qual Life Res"},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1756-9966-32-103","volume":"32","author":"MG Petrongari","year":"2013","unstructured":"Petrongari MG, Landoni V, Saracino B, Gomellini S, Arcangeli S, Iaccarino G, et al. Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. J Exp Clin Cancer Res. 2013;32:103.","journal-title":"J Exp Clin Cancer Res"},{"key":"2103_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17:464\u201374.","journal-title":"Lancet Oncol"},{"key":"2103_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13014-017-0839-3","volume":"12","author":"M Jolnerovski","year":"2017","unstructured":"Jolnerovski M, Salleron J, Beckendorf V, Peiffert D, Baumann AS, Bernier V, et al. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity. Radiat Oncol. 2017;12:99.","journal-title":"Radiat Oncol"},{"key":"2103_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","volume":"97","author":"DA Hamstra","year":"2017","unstructured":"Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97:976\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijrobp.2017.05.035","volume":"99","author":"M Pinkawa","year":"2017","unstructured":"Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ. Quality of life after radiation therapy for prostate cancer with a hydrogel spacer: 5-year results. Int J Radiat Oncol Biol Phys. 2017;99:374\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR35","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00120-013-3290-6","volume":"52","author":"T Klotz","year":"2013","unstructured":"Klotz T, Mathers MJ, Lazar Y, Gagel B. Use of hydrogel as spacer in Denovier\u2019s space: optimization of IMRT radiotherapy of localized prostate cancer. Urologe A. 2013;52:1690\u20137.","journal-title":"Urologe A"},{"key":"2103_CR36","doi-asserted-by":"publisher","first-page":"2014206931","DOI":"10.1136\/bcr-2014-206931","volume":"1","author":"AYM Teh","year":"2014","unstructured":"Teh AYM, Ko HT, Barr G, Woo HH. Rectal ulcer associated with SpaceOAR hydrogel insertion during prostate brachytherapy. BMJ Case Rep. 2014;1:2014206931.","journal-title":"BMJ Case Rep."},{"key":"2103_CR37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1089\/end.2019.0431","volume":"33","author":"A Aminsharifi","year":"2019","unstructured":"Aminsharifi A, Kotamarti S, Silver D, Schulman A. Major complications and adverse events related to the injection of the SpaceOAR hydrogel system before radiotherapy for prostate cancer: review of the manufacturer and user facility device experience database. J Endourol. 2019;33:868\u201371.","journal-title":"J Endourol"},{"key":"2103_CR38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijrobp.2016.02.025","volume":"95","author":"G Habl","year":"2016","unstructured":"Habl G, Uhl M, Katayama S, Kessel KA, Hatiboglu G, Hadaschik B, et al. Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study\u2014the IPI trial. Int J Radiat Oncol. 2016;95:435\u201343.","journal-title":"Int J Radiat Oncol"},{"key":"2103_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.radonc.2017.07.026","volume":"125","author":"Y van Wijk","year":"2017","unstructured":"van Wijk Y, Vanneste BGL, Walsh S, van der Meer S, Ramaekers B, van Elmpt W, et al. Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: comparison of dose, toxicity and cost-effectiveness. Radiother Oncol. 2017;125:107\u201312.","journal-title":"Radiother Oncol"},{"key":"2103_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.radonc.2016.08.026","volume":"121","author":"BGL Vanneste","year":"2016","unstructured":"Vanneste BGL, Hoffmann AL, van Lin EN, Van De Voorde L, Pinkawa M, Lambin P. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? a model-based approach for patient selection. Radiother Oncol. 2016;121:118\u201323.","journal-title":"Radiother Oncol"},{"key":"2103_CR41","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884\u201390.","journal-title":"J Clin Oncol"},{"key":"2103_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fonc.2020.00469","volume":"10","author":"WD Heemsbergen","year":"2020","unstructured":"Heemsbergen WD, Incrocci L, Pos FJ, Heijmen BJM, Witte MG. Local dose effects for late gastrointestinal toxicity after hypofractionated and conventionally fractionated modern radiotherapy for prostate cancer in the HYPRO trial. Front Oncol. 2020;10:469.","journal-title":"Front Oncol"},{"key":"2103_CR43","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325\u201332.","journal-title":"J Clin Oncol"},{"key":"2103_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13014-020-01622-3","volume":"15","author":"F Cuccia","year":"2020","unstructured":"Cuccia F, Mazzola R, Nicosia L, Figlia V, Giaj-Levra N, Ricchetti F, et al. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat Oncol. 2020;15:178.","journal-title":"Radiat Oncol"},{"key":"2103_CR45","doi-asserted-by":"publisher","first-page":"20200848","DOI":"10.1259\/bjr.20200848","volume":"94","author":"F Alongi","year":"2021","unstructured":"Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, et al. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. Br J Radiol. 2021;94:20200848.","journal-title":"Br J Radiol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02103-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T18:15:01Z","timestamp":1658772901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02103-5","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Epworth HealthCare (611-13) and Monash Health (RES-19-0000-167E) human research ethics committees, respectively. All patients provided written informed consent prior to enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}